Immunotherapy for HPV+ head and neck cancer: Awakening the force within. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2021 / 09 / 210901113718.htm ...

ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 ...

(RTTNews) - Aprea Therapeutics, Inc.(APRE), a clinical-stage biopharmaceutical company, Monday announced that it has dosed a patient with HPV+ Head and Neck Squamous Cell Carcinoma or HNSCC in its ...

APR-1051 potentiatiated the immune response to checkpoint inhibitors in an HPV+ HNSCC model. Clinical Update from Phase 1 ACESOT‑1051 Trial:. In a 62-year-old male with advanced HPV-positive ...

APR-1051 demonstrated robust antiproliferative effects across a broad panel of human and murine head and neck cancer cell lines, including HPV+ subtypes, with IC₅₀ values ranging from 8.9 to ...

The group's pre-clinical research in cell lines and mouse models of HPV+ cancers shows that fenofibrate performed as well against these cancers as the conventional chemotherapy drug cisplatin.

Through this collaboration, Dana-Farber and Repertoire aim to identify novel tumor antigen targets relevant to HPV+ head and neck tumors that will be used to inform the development of novel ...